NCT00655044已完成不适用
Observational, Safety Study in Subjects Using Levemir® (Insulin Detemir) for the Treatment of Type 1 or Type 2 Diabetes Mellitus
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 3,637
- 试验地点
- 1
- 主要终点
- HbA1C
研究概览
简要总结
This study is conducted in Europe. The aim of this observational study is to evaluate the incidence of serious adverse drug reactions while using Levemir® under normal clinical practice conditions.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Type 1 diabetes
- •Type 2 diabetes
- •Candidates of use of a basal insulin as part of their diabetes regimen
排除标准
- •Unwilling to adhere to therapy or follow up
- •Pregnancy
研究组 & 干预措施
Type 1 and type 2 diabetes patients
干预措施: insulin detemir (Drug)
结局指标
主要结局
HbA1C
时间窗: after 12 weeks
次要结局
- Safety(during treatment)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Observational Study to Evaluate the Safety and Efficacy of NovoMix® 70 in Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT00704223Novo Nordisk A/S619
已完成
不适用
An Observational Study of Type 2 Diabetes in Patients Starting on NovoMix® 30 TreatmentDiabetesDiabetes Mellitus, Type 2NCT00696995Novo Nordisk A/S509
已完成
不适用
Observational Study to Evaluate the Safety of Levemir® in DiabetesDiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2NCT00706017Novo Nordisk A/S2,282
已完成
不适用
Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix InsulinDiabetes Mellitus, Type 2DiabetesNCT00775736Novo Nordisk A/S611
已完成
不适用
Observational Study to Evaluate Safety of Levemir® in Type 1 and Type 2 DiabetesDiabetes Mellitus, Type 1DiabetesDiabetes Mellitus, Type 2NCT00700765Novo Nordisk A/S1,531